1. Reducing Time to Market with Targeted Regulatory Affairs Support

    Regulatory affairs activities are essential components of any drug development and commercialization program, explains Maryse Phan, Head of Regulatory Affairs for API Manufacturing, Servier CDMO.

  2. Overcoming Formulation Challenges with Liquid-fill Capsules
    Eli Elias, Director of Business Development for CapsCanada discusses how liquid-filled hard-shell capsules enable formulators to overcome challenges with complex API.
  3. Oral Solid Dose Manufacturing Efficiency is Driving New Attention to Plant Design

    Witold Lehmann, PE, Senior Process Engineer for CRB USA explains the drivers behind strategic planning and efficient production.

  4. Building a Biologics Business from the Ground Up

    Achieving success requires the right strategy, explains Hannes Teissl, Vice President, Biologics at Polpharma Biologics.

  5. DOPING – Famous Cases, Substances and Values in Sports

    Doping remains a constant threat to the ethics and values in professional sports, as well as on the amateur level.

  6. Five Tips to Ensure Faster Equipment Procurement and Installation
    Used equipment is readily available, cuts lead time for delivery and install, and allows faster product launch, says Jim Coyne, Business Development/Sales at Federal Equipment Company.
  7. Roche and Foundation Medicine Reach Definitive Merger Agreement to Accelerate Broad Availability of Comprehensive Genomic Profiling in Oncology

    Together, the companies will leverage expertise in genomics and molecular information to enhance the development of personalized medicines and care for patients with cancer.

  8. Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801

    Up to 48 subjects will be enrolled, including 24 healthy volunteers and 24 subjects with type 1 diabetes.

  9. Progress on New Antiviral Drugs at Chimerix

    Company reports positive results for treatments against smallpox and norovirus.

  10. Successful IPO for Verrica Pharmaceuticals

    Company raised $75 million, which will be used to fund a phase 3 study for its treatment of skin infections.

     

  11. Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure

    Paris, France and Ghent, Belgium - Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx announced today that Sanofi has now acquired all outstanding shares (including shares represented by American Depositary Shares ("ADSs")), warrants and convertible bonds (together, the "Securities") of Ablynx NV ("Ablynx") following the expiration of the Squeeze-out procedure. 

    The Squeeze-out period commenced on May 22, 2018, in accordance with applicable Belgian and U.S. law, following the acquisition by Sanofi of over 95% of the outstanding shares of Ablynx upon settlement of the initial acceptance period of its tender offer for Ablynx.

    On June 12, 2018, upon expiration of the Squeeze-out period, 2,893,201 shares (including 7,163 shares represented by ADSs) and 8 convertible bonds of Ablynx were tendered in the Squeeze-out.

    The Securities tendered during the Squeeze-out period are expected to be settled on or about June 19, 2018.

    All shares (including all shares represented by ADSs) and all convertible bonds of Ablynx not tendered during the Squeeze-out are deemed transferred to Sanofi by operation of law. The funds required for the payment of the price thereof are kept with the Bank for Official Deposits (Deposito- en Consignatiekas / Caisse des dépôts et consignations). The former Ablynx holders of these Securities retain the right to receive EUR 45.00 per share (or ADS) and EUR 393,700.78 per convertible bond. In order to receive these amounts, they must contact the Bank for Official Deposits, where the funds will remain available. 

    On June 13, 2018, (i) the shares of Ablynx were delisted from the regulated market of Euronext Brussels, (ii) the ADSs were delisted from NASDAQ Global Select Market and (iii) the convertible bonds were delisted from the open market Frankfurt MTF (Freiverkehr).

    Sanofi contacts

     

    Media Relations Contact
    Laurence Bollack

    Tel.: +33 (0)1 53 77 46 46
    mr@Sanofi.com

     




     

    Investor Relations Contact
    George Grofik

    Tel.: +33 (0)1 53 77 45 45
    ir@Sanofi.com

     

    Ablynx contacts


     

    Dr Edwin Moses
    CEO 
    Tel.:+32 (0)9 262 00 07
    Mob.: +32 (0)473 39 50 68
    edwin.moses@ablynx.com

     




     

    Lies Vanneste
    Director IR 
    Tel.: +32 (0)9 262 0137
    Mob: +32 (0)498 05 35 79 
    lies.vanneste@ablynx.com
     
  12. Building Healthcare Brands through Recognizable Capsules

    Differentiation and establishment of brand recognition are as important for drug products as they are for consumer goods, says Jim Taggart, Plant Manager, CapsCanada.

  13. Optimizing API Production as a True Manufacturing Partner

    Jim Scandura, Executive Vice President, Chief Operating Officer at Avara Pharmaceutical Service discusses serving as a partner for API production.

  14. Scientific Expertise Facilitates Oral Peptide Product Development and Manufacturing

    Ariana Nagel, Director of Product Development, R&D and and Matthew Ferrell, Director of Analytical Development at UPM Pharmaceuticals explain the benefits and challenges of peptide therapies.

  15. Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing

    Richard Snyder, Ph.D., Chief Scientific Officer and Founder; Christopher Murphy, Chief Manufacturing Officer; Susan D'costa, VP Development and Cameron Jones, Quality Assurance Director at Brammer Bio explain how to strengthen security of supply in viral vector manufacturing.

  16. Meeting Biopharma Contract Manufacturing Needs with a Flexible Global Network

    Gustavo Mahler, President & CEO of AGC Biologics discusses the increasing need for CDMO support to provide with advanced capabilities and technology platforms across scales and geographies. 

    President & CEOAGC Biologics
  17. Using a Risk-Based Approach to Manufacturing in a Multi-Product Facility

    Peter Boeddeker, Director of Quality Management at Baxter BioPharma Solutions describes the challenges and advantages of multi-product facilities.

  18. Cellectic CAR-T Therapy Contains Safety Switch and More
    CubiCAR cells are designed to be killed by the monoclonal antibody, rituximab, in patients with an overactive immune response.
  19. New Diagnostic Tool for Heart Disease Based on CRISPR Technology

    Researchers at Stanford University developed the tool, which combines gene editing and disease modeling.

  20. A Key to the Cage: Opening the Living Membrane Gate

    For the first time ever, scientists have accurately described the process of pore formation in lipid membranes and carried out computer simulations of their formation and evolution.

THE ROAD TO BIO: THE EXTENDED STORY
View All

Road To BIO: Coming Soon To Your Screen Q4 2018
The Road to BIO in Review
The Road To BIO: Day 12 California
The Road To BIO: Day 11 Arizona /// California
The Road To BIO: Day 10 Texas /// Arizona
The Road To BIO: Day 9 Texas
The Road To BIO: Day 8 Texas
The Road To BIO: Day 7 Mississippi /// Texas
The Road To BIO: Day 6 Georgia /// Mississippi
The Road To BIO: Day 5 South Carolina /// Georgia
The Road To BIO: Day 4 Tennessee /// South Carolina
The Road To BIO: Day 3 Pennsylvania /// Tennessee
The Road To BIO: Day 2 New York /// Pennsylvania
For Your Listening Pleasure
The full story of this epic journey can be experienced as an audiobook. Listen to the story behind the story – the characters, the challenges, and all 12 days of the Road To BIO.
Nice Insight Awareness/Perception Scorecard

Research. Compare. Contact. Find the Ideal Partner.

Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.

  1. Search by company type, region, market segment and services.
  2. Select up to 5 companies to compare.
  3. View CA & CP performance scores against industry benchmark ratings.
SEARCH COMPANIES
Capsules

Building Healthcare Brands through Recognizable Capsules

Jun 21, 2018 11:08:36 AM PAO-06-18-CL-004
Antiviral

Progress on New Antiviral Drugs at Chimerix

Jun 21, 2018 10:30:39 AM PAO-M06-18-NI-019
Investment

Successful IPO for Verrica Pharmaceuticals

Jun 21, 2018 10:22:44 AM PAO-M06-18-NI-018
CAR-T Therapy

Cellectic CAR-T Therapy Contains Safety Switch and More

Jun 21, 2018 10:15:26 AM PAO-M06-18-NI-017
CRISPR

New Diagnostic Tool for Heart Disease Based on CRISPR Technology

Jun 21, 2018 10:11:07 AM PAO-M06-18-NI-016
Regulatory

Reducing Time to Market with Targeted Regulatory Affairs Support

Jun 20, 2018 10:31:31 AM PAO-06-18-CL-003
Drug Discovery

Could a Bispecific Antibody Be A Functional Cure for AIDS?

Jun 19, 2018 1:14:03 PM PAO-M06-18-NI-015
Drug Development

China Grants First Approval for PD-1/L1 Checkpoint Inhibitor

Jun 19, 2018 1:11:20 PM PAO-M06-18-NI-014
Announcement

French Pharma Company Ipsen Moves US Headquarters from New Jersey to Boston

Jun 15, 2018 1:00:09 PM PAO-M06-18-NI-013
Cell and Gene Therapy

Will Rapid Genome Sequencing Become A Standard Practice for Acutely Ill Infants?

Jun 15, 2018 12:53:46 PM PAO-M06-18-NI-012
Oral Solid Dose

HPAPI’s and Two-Piece Liquid-Fill Capsules: The Perfect Match

Jun 14, 2018 3:42:01 PM PAO-06-18-CL-001
Oncology

Hormone Therapy Appears to Be the Best Bet for Treating Early Breast Cancer

Jun 14, 2018 1:00:03 PM PAO-M06-18-NI-011
Investment

Pfizer Expands Investment in Biotech through Pfizer Ventures

Jun 14, 2018 12:55:15 PM PAO-M06-18-NI-010
Combination Treatment

FDA Approves Venclexta/Rituxan Combination Treatment for Leukemia

Jun 12, 2018 2:35:44 PM PAO-M06-18-NI-009
Opiods

Preliminary Data Suggests DENKI Pain Blockers Don’t Have Abuse Potential

Jun 12, 2018 2:29:55 PM PAO-M06-18-NI-008
Columns

Nice Insight Overview

Changes in the  Biopharma Industry: from Minor to Major Evolution
New technologies such as gene editing are leading to the development of even more advanced, targeted medicines.

The Next-Generation Player

Addressing Development Challenges for Complex Biologic Drug Candidates
At Lonza, we are constantly looking to reduce the development timeline, giving our customers more control over their projects.


Karen Fallen, Vice President, Business Unit Head of Clinical Development & Manufacturing Lonza Pharma & Biotech

M+A Column

Inside Mergers & Acquisitions
Kevin Bottomley Partner, Results Healthcare
Deals in the pharmaceutical industry are an important mechanism of acquiring innovation, business and efficiency.

Nice Insight Overview

Doping: Famous Cases, Substances and Values in Sports

Marc Technow, Nice Insight